EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Central Nervous System Targeted Protein Degraders

Bedwyr Ab Ion Thomas iD, H Lois Lewis, D Heulyn Jones, Simon E Ward iD

Biomolecules · 25.07.2023 · 13 (8) · 1164

DOI: 10.3390/biom13081164 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Biomolecules, online erschienen am 25.07.2023. Verfasst von Bedwyr Ab Ion Thomas und 3 weiteren Autor:innen. Beteiligte Einrichtung: Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, UK. Hauptthemen laut MEDLINE: Central Nervous System, Brain. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 117 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Coleg Cymraeg Cenedlaethol, Janssen.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diseases of the central nervous system, which once occupied a large component of the pharmaceutical industry research and development portfolio, have for many years played a smaller part in major pharma pipelines—primarily due to the well cited challenges in target validation, valid translational models, and clinical trial design. Unfortunately, this decline in research and development interest has occurred in tandem with an increase in the medical need—in part driven by the success in treating other chronic diseases, which then results in a greater overall longevity along with a higher prevalence of diseases associated with ageing. The lead modality for drug agents targeting the brain remains the traditionally small molecule, despite potential in gene-based therapies and antibodies, particularly in the hugely anticipated anti-amyloid field, clearly driven by the additional challenge of effective distribution to the relevant brain compartments. However, in recognition of the growing disease burden, advanced therapies are being developed in tandem with improved delivery options. Hence, methodologies which were initially restricted to systemic indications are now being actively explored for a range of CNS diseases—an important class of which include the protein degradation technologies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Central Nervous SystemBrainAntibodiesAmyloidogenic Proteins

Stichwörter der Autor:innen

CNSPROTACstargeted protein degraders

Substanzen

AntibodiesAmyloidogenic Proteins

Autor:innen und Institutionen

  • Medicines Discovery Institute, Cardiff University, Cardiff CF10 3AT, UK.
  • Chemistry Department, Cardiff University, Cardiff CF10 3AT, UK.

ORCID-Profile: Bedwyr Ab Ion Thomas, Simon E Ward

Förderung

  • Coleg Cymraeg Cenedlaethol
  • Janssen

Zitieren

APA

Thomas, B. A. I., Lewis, H. L., Jones, D. H., & Ward, S. E. (2023). Central Nervous System Targeted Protein Degraders. Biomolecules, 13(8), 1164. https://doi.org/10.3390/biom13081164

Vancouver

Thomas BAI, Lewis HL, Jones DH, Ward SE. Central Nervous System Targeted Protein Degraders. Biomolecules. 2023;13(8):1164. doi:10.3390/biom13081164

BibTeX
@article{Thomas2023,
  author = {Thomas, Bedwyr Ab Ion and Lewis, H Lois and Jones, D Heulyn and Ward, Simon E},
  title = {Central Nervous System Targeted Protein Degraders},
  journal = {Biomolecules},
  year = {2023},
  volume = {13},
  number = {8},
  pages = {1164},
  doi = {10.3390/biom13081164}
}
Kostenlos starten →